×
About 7,240 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  3,497 results

New advances in radiomics of gastrointestinal stromal tumors.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459199
World Journal of Gastroenterology; Cannella R, La Grutta L et. al.

Sep 14th, 2020 - Gastrointestinal stromal tumors (GISTs) are uncommon neoplasms of the gastrointestinal tract with peculiar clinical, genetic, and imaging characteristics. Preoperative knowledge of risk stratification and mutational status is crucial to guide the ...

Efficacy of endoscopic ultrasound with artificial intelligence for the diagnosis of gas...
https://doi.org/10.1007/s00535-020-01725-4
Journal of Gastroenterology; Minoda Y, Ihara E et. al.

Sep 12th, 2020 - Although endoscopic ultrasound (EUS) is reported to be suitable for determining the layer from which subepithelial lesions (SELs) originate, it is difficult to distinguish gastrointestinal stromal tumor (GIST) from non-GIST using only EUS images. ...

Internet-Delivered Cognitive Behavioral Therapy and Psychoeducation Program for Patient...
https://doi.org/10.1007/s13187-020-01866-3
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education; Carbajal-López EB, Juárez-García DM et. al.

Sep 7th, 2020 - Gastrointestinal stromal tumors (GIST) account for 0.2-3% of all cancer diagnoses and are thus considered a rare type of cancer. Severe levels of fatigue occur in 33% of patients on imatinib, but besides treatment, fatigue is also associated with ...

Clinical and prognostic significance of CC chemokine receptor type 8 protein expression...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445867
World Journal of Gastroenterology; Li HL, Wang LH et. al.

Sep 4th, 2020 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Surgical resection and tyrosine kinase inhibitors are defined as the main treatments but cannot cure patients with advanced GIST, whic...

Succinate dehydrogenase-deficient gastrointestinal stromal tumor of stomach diagnosed b...
https://doi.org/10.1002/dc.24591
Diagnostic Cytopathology REFERENCES; Gokozan HN, Bomeisl P

Sep 1st, 2020 - Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are characterized by the lack of mutations in KIT receptor tyrosine kinase complex and platelet derived growth factor receptor-alpha (PDGFRA) that are commonly found i...

see more →

Guidelines  11 results

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 25th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, t...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy095/5004450
Casali, P. G.

May 27th, 2018 - Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year. This only covers clinically relevant GISTs, since, if investigated, a much higher number of lesions ≤ 1 cm in diameter (mic.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Bellera CA, Penel N et. al.

Jul 29th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3,627 results

New advances in radiomics of gastrointestinal stromal tumors.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459199
World Journal of Gastroenterology; Cannella R, La Grutta L et. al.

Sep 14th, 2020 - Gastrointestinal stromal tumors (GISTs) are uncommon neoplasms of the gastrointestinal tract with peculiar clinical, genetic, and imaging characteristics. Preoperative knowledge of risk stratification and mutational status is crucial to guide the ...

Efficacy of endoscopic ultrasound with artificial intelligence for the diagnosis of gas...
https://doi.org/10.1007/s00535-020-01725-4
Journal of Gastroenterology; Minoda Y, Ihara E et. al.

Sep 12th, 2020 - Although endoscopic ultrasound (EUS) is reported to be suitable for determining the layer from which subepithelial lesions (SELs) originate, it is difficult to distinguish gastrointestinal stromal tumor (GIST) from non-GIST using only EUS images. ...

Internet-Delivered Cognitive Behavioral Therapy and Psychoeducation Program for Patient...
https://doi.org/10.1007/s13187-020-01866-3
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education; Carbajal-López EB, Juárez-García DM et. al.

Sep 7th, 2020 - Gastrointestinal stromal tumors (GIST) account for 0.2-3% of all cancer diagnoses and are thus considered a rare type of cancer. Severe levels of fatigue occur in 33% of patients on imatinib, but besides treatment, fatigue is also associated with ...

Clinical and prognostic significance of CC chemokine receptor type 8 protein expression...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445867
World Journal of Gastroenterology; Li HL, Wang LH et. al.

Sep 4th, 2020 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Surgical resection and tyrosine kinase inhibitors are defined as the main treatments but cannot cure patients with advanced GIST, whic...

Succinate dehydrogenase-deficient gastrointestinal stromal tumor of stomach diagnosed b...
https://doi.org/10.1002/dc.24591
Diagnostic Cytopathology REFERENCES; Gokozan HN, Bomeisl P

Sep 1st, 2020 - Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are characterized by the lack of mutations in KIT receptor tyrosine kinase complex and platelet derived growth factor receptor-alpha (PDGFRA) that are commonly found i...

see more →

News  99 results

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

FDA approves avapritinib for adults with GIST with PDGFRA mutation
https://www.mdedge.com/sarcomajournal/article/215340/gastroenterology/fda-approves-avapritinib-adults-gist-pdgfra-mutation?channel=27979
Lucas Franki

Jan 10th, 2020 - The Food and Drug Administration has approved avapritinib (Ayvakit) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with a platelet-derived growth factor receptor–alpha (PDGFRA) exon 18 mutation.

FDA Awards Grant To Study Temozolomide in Gist
https://www.mdedge.com/sarcomajournal/article/215292/oncology/fda-awards-grant-study-temozolomide-gist?channel=39313

Jan 9th, 2020 - A phase 2 study of temozolomide in gastrointestinal stromal tumors (GIST) received one of the 12 grants awarded in October by the US Food and Drug Administration (FDA) to enhance the development of medical products for patients with rare diseases.

Deciphera shares skyrocket as cancer drug improves progression-free survival
https://www.reuters.com/article/us-deciphera-study/decipheras-late-stage-study-meets-main-goal-of-preventing-cancer-progression-idUSKCN1V30ZJ

Aug 13th, 2019 - (Reuters) - Deciphera Pharmaceuticals Inc’s shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study. The treatment, ripretinib, was...

see more →

Patient Education  4 results see all →